fluoxetine has been researched along with eszopiclone in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Choi, Y; Raymer, BK | 1 |
| Banasr, M; Duman, RS; Li, XY; Su, XW | 1 |
| Blocker, JN; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB | 1 |
| Barry, N; Botteman, MF; Pickard, AS; Sarocco, P; Schaefer, K; Snedecor, SJ | 1 |
| Feetam, CL; Nutt, DJ | 1 |
| Blocker, JN; Boggs, N; D'Agostino, R; Haskett, R; Kimball, J; Krystal, A; Lasater, B; McCall, WV; McDonald, WM; Rosenquist, PB | 1 |
| Fava, M; Huang, H; Iosifescu, DV; Mischoulon, D; Schaefer, K; Wessel, TC; Wilson, A | 1 |
| Blocker, J; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB | 1 |
| Brown, RW; Chandley, M; Duffourc, M; Huggins, KN; Noel, DM; Ordway, GA; Smith, JJ; Smith, ML; Szebeni, A; Szebeni, K | 1 |
| McCall, C; McCall, WV | 1 |
2 review(s) available for fluoxetine and eszopiclone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Sleep modulating agents.
Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents | 2019 |
6 trial(s) available for fluoxetine and eszopiclone
| Article | Year |
|---|---|
Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Eszopiclone; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Suicidal Ideation; Young Adult | 2010 |
Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Topics: Absenteeism; Algorithms; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Cost of Illness; Cost-Benefit Analysis; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Eszopiclone; Fluoxetine; Humans; Hypnotics and Sedatives; Personality Inventory; Piperazines; Psychometrics; Quality-Adjusted Life Years | 2010 |
Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Eszopiclone; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Patient Satisfaction; Personality Inventory; Piperazines; Quality of Life; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2010 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Eszopiclone; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Piperazines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2011 |
Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs.
Topics: Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder; Drug Therapy, Combination; Eszopiclone; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Piperazines; Placebo Effect; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep; Sleep Initiation and Maintenance Disorders; Wakefulness | 2011 |
Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?
Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Eszopiclone; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Piperazines; Polysomnography; Self-Assessment; Sleep; Sleep Initiation and Maintenance Disorders; Young Adult | 2012 |
4 other study(ies) available for fluoxetine and eszopiclone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Eszopiclone and fluoxetine enhance the survival of newborn neurons in the adult rat hippocampus.
Topics: Age Factors; Animals; Animals, Newborn; Azabicyclo Compounds; Cell Survival; Drug Combinations; Eszopiclone; Fluoxetine; Hippocampus; Male; Neurons; Piperazines; Rats; Rats, Sprague-Dawley | 2009 |
What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology.
Topics: Animals; Azabicyclo Compounds; Citalopram; Eszopiclone; Fluoxetine; Humans; Mental Disorders; Molecular Structure; Piperazines; Psychotropic Drugs; Rats; Selective Serotonin Reuptake Inhibitors; Stereoisomerism | 2010 |
Eszopiclone facilitation of the antidepressant efficacy of fluoxetine using a social defeat stress model.
Topics: Animals; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Depression; Dose-Response Relationship, Drug; Drug Synergism; Eszopiclone; Fluoxetine; Hypnotics and Sedatives; Interpersonal Relations; Male; Mice; Mice, Inbred C57BL; Piperazines; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta; Social Environment; Stress, Psychological | 2011 |